EP1037610A4 - Liposomale camptothecin formulierungen - Google Patents

Liposomale camptothecin formulierungen

Info

Publication number: EP1037610A4
Authority: EP; European Patent Office
Prior art keywords: liposomal camptothecin; camptothecin formulations; formulations; liposomal; camptothecin
Prior art date: 1997-09-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP98946983A

Other languages

English (en)

French (fr)

Other versions

EP1037610A1 (de

Inventor

Karen Lewis Moynihan

David Lloyd Emerson

Su-Ming Chiang

Ning Hu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

OSI Pharmaceuticals LLC

Original Assignee

OSI Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-16

Filing date

1998-09-15

Publication date

2004-07-07

1998-09-15 Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC

2000-09-27 Publication of EP1037610A1 publication Critical patent/EP1037610A1/de

2004-07-07 Publication of EP1037610A4 publication Critical patent/EP1037610A4/de

Status Withdrawn legal-status Critical Current

Links

KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
229940127093 camptothecin Drugs 0.000 title 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP98946983A 1997-09-16 1998-09-15 Liposomale camptothecin formulierungen Withdrawn EP1037610A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5908397P	1997-09-16	1997-09-16
US59083P		1997-09-16
PCT/US1998/019086 WO1999013816A2 (en)	1997-09-16	1998-09-15	Liposomal camptothecin formulations

Publications (2)

Publication Number	Publication Date
EP1037610A1 EP1037610A1 (de)	2000-09-27
EP1037610A4 true EP1037610A4 (de)	2004-07-07

Family

ID=22020747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP98946983A Withdrawn EP1037610A4 (de)	1997-09-16	1998-09-15	Liposomale camptothecin formulierungen

Country Status (8)

Country	Link
EP (1)	EP1037610A4 (de)
JP (1)	JP2003510239A (de)
KR (1)	KR100711315B1 (de)
AU (1)	AU751439B2 (de)
BR (1)	BR9812316A (de)
CA (1)	CA2303366A1 (de)
NZ (1)	NZ503293A (de)
WO (1)	WO1999013816A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE238039T1 (de)	1998-09-16	2003-05-15	Alza Corp	In liposomen eingeschlossene topoisomerase inhibitoren
US7311924B2 (en)	1999-04-01	2007-12-25	Hana Biosciences, Inc.	Compositions and methods for treating cancer
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
DE60115044T2 (de) *	2000-06-30	2006-08-03	Inex Pharmaceuticals Corp., Burnaby	Liposomale antineoplastische arzneimittel und deren verwendungen
US7452550B2 (en)	2000-06-30	2008-11-18	Hana Biosciences, Inc.	Liposomal antineoplastic drugs and uses thereof
DE60136490D1 (de) *	2000-11-09	2008-12-18	Neopharm Inc	Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
DE10157994A1 (de) *	2001-05-25	2003-01-02	G O T Therapeutics Gmbh	Liposomal verkapselte hydrophobe Wirkstoffe mit hohem Wirkstoffgehalt >50% sowie Verfahren zur Herstellung pharmazeutischer Zubereitungen, die liposomal verkapselte hydrophobe Wirkstoffe umfassen
WO2003030864A1 (en)	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
EP1393719A1 (de) *	2002-08-23	2004-03-03	Munich Biotech AG	Camptothecin-Carboxylat Formulierungen
WO2004002455A1 (en) *	2002-06-26	2004-01-08	Medigene Oncology Gmbh	Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
WO2004047800A2 (en) *	2002-11-26	2004-06-10	Gilead Sciences, Inc.	Method of drug loading in liposomes by gradient
JP4990786B2 (ja) *	2004-11-05	2012-08-01	イネックスファーマシューティカルズコーポレイション	薬物リポソーム製剤を安定化するための組成物および方法
WO2008070009A2 (en) *	2006-12-01	2008-06-12	Alza Corporation	Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
CN101209243B (zh) *	2006-12-29	2010-12-08	石药集团中奇制药技术（石家庄）有限公司	一种脂质体药物及其制备方法
TWI428135B (zh)	2007-03-26	2014-03-01	Hirofumi Takeuchi	And a carrier composition for quick-acting nucleic acid delivery
KR101130754B1 (ko)	2010-06-25	2012-03-28	제일약품주식회사	난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
AU2013203682B2 (en) *	2011-08-25	2016-03-31	Trophos	Liposome comprising at least one cholesterol derivative
FR2979239A1 (fr) *	2011-08-25	2013-03-01	Trophos	Liposome comprenant au moins un derive de cholesterol
WO2014047116A1 (en) *	2012-09-18	2014-03-27	Comfort Care For Animals Llc	Encapsulating liposomes
KR102310697B1 (ko)	2012-11-20	2021-10-12	스펙트럼 파마슈티컬즈 인크	치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
TWI678213B (zh)	2015-07-22	2019-12-01	美商史倍壯製藥公司	用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
KR102162351B1 (ko)	2018-11-08	2020-10-06	순천향대학교 산학협력단	약물-결합 화합물 및 이의 용도
CN115721610B (zh) *	2021-08-27	2024-10-25	沈阳药科大学	一种7-乙基-10-羟基喜树碱复方脂质体及其制备方法和应用
CN116327701A (zh) *	2023-02-27	2023-06-27	北京大学深圳医院（北京大学深圳临床医学院）	用于治疗肝纤维化的复合纳米脂质体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995008986A1 (en) *	1993-09-27	1995-04-06	Smithkline Beecham Corporation	Camptothecin formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5559235A (en) *	1991-10-29	1996-09-24	Glaxo Wellcome Inc.	Water soluble camptothecin derivatives
US5552156A (en) *	1992-10-23	1996-09-03	Ohio State University	Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) *	1993-05-28	1996-09-10	Aphios Corporation	Methods and apparatus for making liposomes

1998
- 1998-09-15 BR BR9812316-5A patent/BR9812316A/pt not_active Application Discontinuation
- 1998-09-15 EP EP98946983A patent/EP1037610A4/de not_active Withdrawn
- 1998-09-15 CA CA002303366A patent/CA2303366A1/en not_active Abandoned
- 1998-09-15 JP JP2000511445A patent/JP2003510239A/ja active Pending
- 1998-09-15 WO PCT/US1998/019086 patent/WO1999013816A2/en not_active Ceased
- 1998-09-15 NZ NZ503293A patent/NZ503293A/xx unknown
- 1998-09-15 AU AU93877/98A patent/AU751439B2/en not_active Ceased
- 1998-09-15 KR KR1020007002701A patent/KR100711315B1/ko not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995008986A1 (en) *	1993-09-27	1995-04-06	Smithkline Beecham Corporation	Camptothecin formulations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURKE T G ET AL: "STABILIZATION OF TOPOTECAN IN LOW PH LIPOSOMES COMPOSED OF DISTEAROYLPHOSPHATIDYLCHOLINE", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 83, no. 7, 1 July 1994 (1994-07-01), pages 967 - 969, XP000454801, ISSN: 0022-3549 *
CULLIS PR, MAYER LD, BALLY MB, MADDEN TD, HOPE MJ: "Generating and loading of liposomal systems for drug-delivery applications", ADVANCED DRUG DELIVERY REVIEWS, vol. 3, 1989, pages 267 - 282, XP002279310 *
DAOUD S S ET AL: "ANTITUMOR EFFECT OF LIPOSOME-INCORPORATED CAMPTOTHECIN IN HUMAN MALIGNANT XENOGRAFTS", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 6, no. 1, 1995, pages 83 - 93, XP000878680, ISSN: 0959-4973 *
See also references of WO9913816A3 *
SUGARMAN S ET AL: "LIPOSOMAL CAMPTOTHECIN: FORMULATION AND CYTOTOXICITY AGAINST KB CELLS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ORLANDO, MAY 19 - 22, 1993, PHILADELPHIA, AACR, US, vol. MEETING 84, 1 March 1993 (1993-03-01), pages 422, XP000578376, ISSN: 0197-016X *

Also Published As

Publication number	Publication date
WO1999013816A3 (en)	2001-11-01
KR20010030599A (ko)	2001-04-16
EP1037610A1 (de)	2000-09-27
BR9812316A (pt)	2001-03-20
NZ503293A (en)	2002-09-27
KR100711315B1 (ko)	2007-04-27
AU751439B2 (en)	2002-08-15
JP2003510239A (ja)	2003-03-18
CA2303366A1 (en)	1999-03-25
AU9387798A (en)	1999-04-05
WO1999013816A2 (en)	1999-03-25

Legal Events

Date	Code	Title	Description
2000-08-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-09-27	17P	Request for examination filed	Effective date: 20000417
2000-09-27	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2000-09-27	AX	Request for extension of the european patent	Free format text: AL PAYMENT 20000417;LT PAYMENT 20000417;LV PAYMENT 20000417;MK PAYMENT 20000417;RO PAYMENT 20000417;SI PAYMENT 20000417
2001-03-07	D17D	Deferred search report published (deleted)
2002-02-06	D17D	Deferred search report published (deleted)
2003-05-28	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: OSI PHARMACEUTICALS, INC.
2004-06-30	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61K 31/4745 B Ipc: 7A 61K 9/127 A
2004-07-07	A4	Supplementary search report drawn up and despatched	Effective date: 20040526
2004-10-13	17Q	First examination report despatched	Effective date: 20040827
2007-05-02	17Q	First examination report despatched	Effective date: 20040827
2010-03-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-04-07	18D	Application deemed to be withdrawn	Effective date: 20091006
2010-04-30	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1031103 Country of ref document: HK

Publication	Publication Date	Title
GB9715751D0 (en)	1997-10-01	Formulations
IL135295A0 (en)	2001-05-20	2-methyl-thieno-benzodiazepine formulation
EP1020193A4 (de)	2006-05-24	Orale präparation
GB9713149D0 (en)	1997-08-27	Pharmaceutical formulations
EP0721328A4 (de)	1997-09-17	Camptothecin-formulierungen
GB2323531B (en)	2001-02-21	Therapeutic formulations
ZA9811461B (en)	1999-06-22	New formulation
PL335700A1 (en)	2000-05-08	Novel preparation
PL337970A1 (en)	2000-09-11	Novel preparation
GB9715490D0 (en)	1997-10-01	Pharmaceutical preparation
ZA982073B (en)	1998-09-16	Pharmaceutical preparation
IL128589A0 (en)	2000-01-31	Explosive formulations
GB9724544D0 (en)	1998-01-21	Novel Formulation
ZA9810773B (en)	1999-05-27	Revitalisation formulation
IL126664A0 (en)	1999-08-17	Explosive formulations
GB9706957D0 (en)	1997-05-21	Formulation
IL126663A0 (en)	1999-08-17	Explosive formulations
IL126669A0 (en)	1999-08-17	Explosive formulations
GB2316869B (en)	1998-08-12	An antihaemolytic liposomal preparation
HK1031103A (en)	2001-06-01	Liposomal camptothecin formulations
IL126665A0 (en)	1999-08-17	Explosive formulations
GB9704521D0 (en)	1997-04-23	Formulations
GB9703099D0 (en)	1997-04-02	Formulations
GB9703101D0 (en)	1997-04-02	Formulations
GB9703100D0 (en)	1997-04-02	Formulations